In a closely watched pharmaceutical patent infringement case, Novo Nordisk, Inc. and Novo Nordisk A/S secured a stipulated dismissal without prejudice against Orbicular Pharmaceutical Technologies Pvt., Ltd. and co-defendants Cipla Ltd. and Cipla USA, Inc., closing a consolidated patent battle that spanned nearly two years in Delaware District Court. Filed on June 24, 2022, and formally closed on April 11, 2024, Case No. 1:22-cv-00856-CFC-CJB centered on generic manufacturers’ attempts to enter the liraglutide injection market — the active ingredient in Novo Nordisk’s blockbuster obesity treatment Saxenda® — before expiration of an 18-patent portfolio.

For patent attorneys navigating ANDA litigation, IP professionals managing pharmaceutical portfolios, and R&D teams assessing biosimilar entry risks, this case offers strategic intelligence on how innovator pharmaceutical companies deploy expansive patent portfolios to defend against generic competition — and how those disputes resolve short of trial.

Case Overview

The Parties

Patents at Issue

This litigation involved 18 U.S. patents spanning formulation chemistry, drug delivery devices, and therapeutic compositions. This patent cluster covers liraglutide’s pharmaceutical formulation, injection delivery mechanisms, and associated methods — creating a layered exclusivity strategy that is characteristic of innovator pharmaceutical lifecycle management.

• • US8,114,833 — Related to liraglutide formulation
• • US9,265,893 — Related to drug delivery device
• • US8,579,869 — Related to therapeutic compositions
• (And 15 additional patents covering related aspects)

Legal Representation

Plaintiff’s Counsel: Morris, Nichols, Arsht & Tunnell LLP, represented by the highly regarded Delaware IP litigator Jack B. Blumenfeld — a dominant presence in Delaware pharmaceutical patent litigation.

Defendants’ Counsel: Richards Layton & Finger PA, with a defense team including Joseph M. Reisman, William O. Adams, William R. Zimmerman, Kelly E. Farnan, and others — a formidable multi-attorney defense consortium.

The Verdict & Legal Analysis

Litigation Timeline & Procedural History

Novo Nordisk filed the lead case on June 24, 2022, in the U.S. District Court for the District of Delaware, the preferred venue for Hatch-Waxman ANDA litigation due to its specialized judicial experience in pharmaceutical patent disputes and efficient docket management.

The case was subsequently consolidated with related Case No. 1:23-cv-00179 (CFC), which specifically named Orbicular, Cipla Ltd., and Cipla USA, Inc. — a procedural consolidation common in multi-ANDA disputes where the same or overlapping patents are asserted against multiple generic filers targeting the same reference listed drug.

The matter proceeded at the district court (first instance) level and remained active until the April 11, 2024 stipulated dismissal, reflecting an approximately 22-month active litigation period for the Orbicular/Cipla consolidated case. Notably, the case docket reflects no assigned Chief Judge in the data, indicating judicial assignment under standard Delaware District Court procedures. The litigation ran through pleadings and pre-trial phases before the parties reached their stipulated resolution — never advancing to full claim construction or trial on the merits.

Outcome

On April 11, 2024, the Delaware District Court entered a stipulated order of dismissal without prejudice as to Orbicular Pharmaceutical Technologies, Cipla Ltd., and Cipla USA, Inc. Critically, the dismissal was structured to preserve legal optionality for both parties:

• No damages were awarded
• No injunctive relief was granted
• Each party bears its own attorneys’ fees and costs
• The dismissal is without prejudice, meaning claims can potentially be reasserted

Verdict Cause Analysis

The operative legal trigger for this entire dispute was Orbicular’s filing of ANDA No. 217590 containing a Paragraph IV certification — a declaration that Novo Nordisk’s listed patents are invalid, unenforceable, or would not be infringed by the generic product. Under the Hatch-Waxman Act (21 U.S.C. § 355(j)), this Paragraph IV certification constitutes an act of infringement as a matter of law, permitting the innovator to file suit and trigger a 30-month stay of FDA approval.

The stipulated dismissal’s explicit language — affirming that “nothing herein prohibits Orbicular from filing and maintaining a Paragraph IV certification” — is legally significant. Orbicular preserves its right to seek and receive final FDA approval of ANDA No. 217590. This means the dismissal is not a concession of infringement or invalidity; rather, it reflects a negotiated pause in litigation without resolution on the merits.

Legal Significance

Several elements make this resolution strategically noteworthy in the liraglutide patent litigation landscape:

1. Patent Portfolio Depth as Leverage: Novo Nordisk’s assertion of 18 patents across formulation, device, and method claims creates an exceptionally high litigation cost and complexity burden for generic challengers — a deliberate portfolio architecture that may itself drive settlement dynamics.
2. Without Prejudice Preservation: The without-prejudice structure means Novo Nordisk retains the right to re-file if Orbicular pursues market entry, while Orbicular preserves its ANDA rights. This is a tactical holding pattern, not a final resolution.
3. Paragraph IV Certification Preserved: Generic manufacturers will note that maintaining Paragraph IV certification rights is a non-negotiable commercial lifeline — and the stipulation’s explicit carve-out on this point reflects careful drafting to protect future market entry timing.

This case pattern is consistent with broader Hatch-Waxman ANDA litigation trends, where complex multi-patent disputes frequently resolve through negotiated dismissals, consent judgments, or licensing arrangements before trial. Companies in the GLP-1, insulin, and injectable biologics space should expect continued aggressive patent assertion from innovators seeking to extend exclusivity windows.